METTL3 and myocardial infarction: METTL3-overexpressing H9c2 cells were also used to investigate SYD's effects on gene expression.<h4>Results</h4><i>In vivo</i>, SYD treatment significantly improved cardiac function in MI mice, including reduced cardiac hypertrophy, enhanced ejection fraction and fractional shortening, and alleviated myocardial damage, fibrosis, and HF biomarkers.